Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CTR20260784 Bufei Huoxue Capsule Pulmonary Disease, Chronic Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20260784 Bufei Huoxue Capsule Pulmonary Disease, Chronic Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20260784 clinical trial report covering Bufei Huoxue Capsule, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07461675 Atezolizumab Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07461675 Atezolizumab Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07461675 clinical trial report covering Atezolizumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20260900 Beclometasone Dipropionate/Formoterol Fumarate Asthma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20260900 Beclometasone Dipropionate/Formoterol Fumarate Asthma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20260900 clinical trial report covering Beclometasone Dipropionate/Formoterol Fumarate, Phase 3, endpoints, sponsor, geography, readout timing and devel
Read →
CTR20260844 H062 Essential Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20260844 H062 Essential Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20260844 clinical trial report covering H062, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
ChiCTR2600120216 Eptifibatide occlusions Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600120216 Eptifibatide occlusions Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
ChiCTR2600120216 clinical trial report covering Eptifibatide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07464912 TDI-01 Idiopathic Pulmonary Fibrosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07464912 TDI-01 Idiopathic Pulmonary Fibrosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07464912 clinical trial report covering TDI-01, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07464587 TQC-3721 Pulmonary Disease, Chronic Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07464587 TQC-3721 Pulmonary Disease, Chronic Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07464587 clinical trial report covering TQC-3721, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07463235 Cabergoline Prolactinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07463235 Cabergoline Prolactinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07463235 clinical trial report covering Cabergoline, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20260773 Copper (64Cu) Oxodotreotide Neuroendocrine Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20260773 Copper (64Cu) Oxodotreotide Neuroendocrine Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20260773 clinical trial report covering Copper (64Cu) Oxodotreotide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07464327 Risvutatug Rezetecan Non-squamous non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07464327 Risvutatug Rezetecan Non-squamous non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07464327 clinical trial report covering Risvutatug Rezetecan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07465263 SYH2053 Heterozygous familial hypercholesterolemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07465263 SYH2053 Heterozygous familial hypercholesterolemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07465263 clinical trial report covering SYH2053, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07463573 MHB088C Metastatic Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07463573 MHB088C Metastatic Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07463573 clinical trial report covering MHB088C, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →